This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
This was a multicenter, open-label study of ADS-5102 (amantadine) extended-release capsules in subjects with MS and walking impairment who completed study drug treatment for 16 weeks and completed a Week 16 visit in Study ADS-AMT-MS301. All enrolled subjects were to receive ADS-5102 at 137 mg for the first week, 205.5 mg for the second week, and 274 mg for the remainder of the 52-week open-label treatment period. Subjects returned to the clinic for safety and efficacy assessments at Weeks 4, 24, and 52. In addition, a telephone visit for safety assessments was conducted at Week 2 and Week 38. Subjects who withdrew from the study prior to completion of the Week 52 visit had an early termination (ET) visit that included safety and efficacy assessments. Subjects who completed 52 weeks of open-label treatment had a final visit for post-treatment safety follow-up and efficacy assessment at Week 54. All study visits and efficacy assessments were to be scheduled to occur at approximately the same time of day for each individual subject. Each subject's efficacy assessment was to be performed by the same clinical rater, if possible.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
424
Oral capsules
Number of Patients With Adverse Events
The incidence of treatment-emergent adverse events was used as the measure for long-term safety and tolerability of ADS-5102.
Time frame: Through study completion, an average of 1 year.
Timed 25-Foot Walk (Feet/Second) (Baseline Value)
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Time frame: Baseline
Timed 25-Foot Walk (Feet/Second) (Week 24 Value)
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Time frame: 24 weeks
Timed 25-Foot Walk (Feet/Second) (Week 52 Value)
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Time frame: 52 weeks
Timed up and go (Baseline Value)
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adamas Clinical Site
Cullman, Alabama, United States
Adamas Clinical Site
Phoenix, Arizona, United States
Adamas Clinical Site
Phoenix, Arizona, United States
Adamas Clinical Site
Tucson, Arizona, United States
Adamas Clinical Site
Carlsbad, California, United States
Adamas Clinical Site
Fresno, California, United States
Adamas Clinical Site
Fullerton, California, United States
Adamas Clinical Site
Long Beach, California, United States
Adamas Clinical Site
Newport Beach, California, United States
Adamas Clinical Site
Sacramento, California, United States
...and 82 more locations
Time frame: Baseline
Timed up and go (Week 24 Value)
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Time frame: 24 weeks
Timed up and go (Week 52 Value)
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Time frame: 52 weeks
2-Minute Walk Test (Baseline Value)
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
Time frame: Baseline
2-Minute Walk Test (Week 24 Value)
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
Time frame: 24 weeks
2-Minute Walk Test (Week 52 Value)
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
Time frame: 52 weeks